Editors note: A version of this summary was provided by getAbstract.

The internet sparked rapid standardization within value chains, enabling innovative interlopers to break them faster than ever before. Yet, companies that occupy only a small space in an ecosystem risk losing sight of the big picture. Often, these disrupters focus solely on consumer demand without regard for any long-term negative consequences on society. SAP chief innovation officer Max Wessel explains why its in your businesss best interest to develop technology that addresses potential ethical issues from the very start.

The creators of autonomous automobiles carefully considered the moral issues pertaining to the development of technology that enables multiton vehicles to operate in the same space as pedestrians and human-driven transportation, Wessel notes. However, not all technology innovators tread as carefully. Often, disrupters limit their visions to fulfilling consumer demands with cheaper, less complicated, and more accessible products without considering the long-term repercussions of their business models.

M. Wessel and N. Helmer, , MIT Sloan Management Review, March 10, 2020.

The late Clayton Christensens Theory of Interdependence and Modularity holds that when companies develop new technologies, they attempt to manage every aspect of the systems design to optimize performance. For example, Apple initially controlled every part of the iPhones complex system. As the components became standardized, other companies entered the fray to specialize in specific pieces of the system. The internet and other technologies increase modularity in value chains across industries, which enables other businesses to insert themselves into the value chain.

Morally responsible startups develop technology and create ethical benchmarks as if they already dominate the industry. As new developers create products in response to consumer demand in a narrow slice of a system, individuals enjoy the abundance of choice without worrying about the overall negative effect on society. Moreover, the rate of innovation outstrips governments ability to regulate preventively. Thats why the onus of establishing these ethical priorities rests on the innovators.

As an organization, put yourself in the role of standard-bearer, instead of just imagining what you can do to break apart the value chain, Wessel argues. Assuming ethical responsibility for an innovation may decelerate a companys development in the short run but will be a competitive advantage in the long run. Apples attention to privacy protection in its technology may have slowed its progress compared with competitors, but Apple has gained public trust.

Other companies, such as Uber, were late to address certain moral issues but worked to adapt, which arguably helped fend off user backlash.

Create an objective advisory board to review the ethical considerations of your companys activities. Genetic testing firm 23andMe handles possible regulatory and user concerns proactively. Executives created an independent board to review the ethics of the companys activities for example, around its customer data. Such prudence has given 23andMe an edge when dealing with regulatory bodies and made its good intentions more credible for consumers. Taking its responsibility seriously has helped the company create a more solid foundation for future success.

Advisory boards made up of people with different perspectives, backgrounds, and expertise provide guidance on relevant issues and counter the cognitive bias that exists in every organization. In the media industry, for example, established companies such as The New York Times and The Washington Post understand the role they play in society. Relative newcomers building the next generation of communication technology must be aware of the implications of their business models at scale and understand the existing players precautionary measures.

Managements role is crucial. The CEO should provide clear guidance on ethics and infuse those principles into the culture. Dont take shortcuts, even in times of crisis. Google and Apple are stepping up to trace and track infected individuals in response to the COVID-19 crisis, yet they cant disregard privacy considerations, even during a global pandemic.

Takeaways from the session:

Event Notifications

Get periodic email updates on upcoming webinars, panel discussions, and other special events.

Please enter a valid email address

Thank you for signing up

Privacy Policy

Max Wessel (@maxwellelliot) is chief innovation officer at SAP. Karen Dillon (@kardillon) is a former editor of Harvard Business Review, coauthor of three bestselling books with Clayton M. Christensen, and guest editor for MIT SMRs spring 2020 issue. She moderated the session.

Read more from the original source:
Ethics in Technology Innovation: A Live Session at Disruption 2020 - MIT Sloan

Recommendation and review posted by Bethany Smith

Over-the-Counter

The report is a compilation of different studies, including regional analysis where leading regional Direct-To-Consumer (DTC) Genetic Testing markets are comprehensive studied by market experts. Both developed and developing regions and countries are covered in the report for a 360-degree geographic analysis of the Direct-To-Consumer (DTC) Genetic Testing market. The regional analysis section helps readers to become familiar with the growth patterns of important regional Direct-To-Consumer (DTC) Genetic Testing markets. It also provides information on lucrative opportunities available in key regional Direct-To-Consumer (DTC) Genetic Testing markets.

Ask For Discounts, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=248561&utm_source=COD&utm_medium=888

Table of Content

1 Introduction of Direct-To-Consumer (DTC) Genetic Testing Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Direct-To-Consumer (DTC) Genetic Testing Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Direct-To-Consumer (DTC) Genetic Testing Market, By Deployment Model

5.1 Overview

6 Direct-To-Consumer (DTC) Genetic Testing Market, By Solution

6.1 Overview

7 Direct-To-Consumer (DTC) Genetic Testing Market, By Vertical

7.1 Overview

8 Direct-To-Consumer (DTC) Genetic Testing Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Direct-To-Consumer (DTC) Genetic Testing Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Get Complete Report

@ https://www.marketresearchintellect.com/need-customization/?rid=248561&utm_source=COD&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Direct-To-Consumer (DTC) Genetic Testing Market Size, Direct-To-Consumer (DTC) Genetic Testing Market Trends, Direct-To-Consumer (DTC) Genetic Testing Market Growth, Direct-To-Consumer (DTC) Genetic Testing Market Forecast, Direct-To-Consumer (DTC) Genetic Testing Market Analysis Sarkari result, Government Jobs, Sarkari naukri, NMK, Majhi Naukri,

Read more:
Direct-To-Consumer (DTC) Genetic Testing Market Development, Trends, Key Driven Factors, Segmentation And Forecast to 2020-2026 - Cole of Duty

Recommendation and review posted by Bethany Smith

Cryonics Technology Market 2020-2026 research report is an in-depth analysis of the latest trends, market size, status, upcoming technologies, industry drivers, challenges opportunity with key company profiles and strategies of players.The Cryonics Technology Market report also provides the market impact and new opportunities created due to the COVID19 catastrophe.

Download the Sample ToC and understand the COVID19 impact and be smart in redefining business strategies. https://inforgrowth.com/CovidImpact-Request/6335951/cryonics-technology-market

Cryonics TechnologyMarket report 2020-2026, discusses various factors driving or restraining the market, which will help the future market to grow with promising CAGR. This Report encompasses the manufacturers data, including shipment, price, revenue, gross profit, interview record, business distribution, etc., these data tend the consumer to know about the competitors better.

The Cryonics Technology market report covers major market players like Praxair, Cellulis, Cryologics, Cryotherm, KrioRus, VWR, Thermo Fisher Scientific, Custom Biogenic Systems, Oregon Cryonics, Alcor Life Extension Foundation, Osiris Cryonics, Sigma-Aldrich, Southern Cryonics

The worldwide Cryonics Technologymarket for Industry is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2026, from xx million US$ in 2019, according to a new study.

Get Exclusive Free Sample of Report on Cryonics Technology market is available at https://inforgrowth.com/sample-request/6335951/cryonics-technology-market

Research MethodologyTo get complete information onCryonics Technology Market, researchers of this report have opted for a bottom-up and top-down approach. The bottom-up approach gives access to the numbers for each product, and the top-down approach helps in counter-validating those numbers with end-use market numbers. The figures mentioned in theCryonics TechnologyMarketreport are equally justified along with examples as per need. It also helps in creating clear knowledge about the market, and as to what rate it is expected to grow in the next six to seven years.

Cryonics Technology Market 2020-2025: Segmentation

Cryonics Technology Market is segmented as below:

Breakup Product Type:Slow freezing, Vitrification, Ultra-rapid

Breakup by Application:Animal husbandry, Fishery science, Medical science, Preservation of microbiology culture, Conserving plant biodiversity

Geographic segmentation

To know about the global trends impacting the future of market research, contact at: https://inforgrowth.com/enquiry/6335951/cryonics-technology-market

Key Questions Answered

How has the aerospace and defense industry opened new avenues for the growth of the Cryonics Technology?

Purpose to Purchase This Report:

Get Special Discount UP TO 50% for this Report: https://inforgrowth.com/discount/6335951/cryonics-technology-market

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USAContact Name: Rohan S.Email:[emailprotected]Phone: +1-909-329-2808UK: +44 (203) 743 1898Website: http://www.inforgrowth.com

Read the original post:
Cryonics Technology Market 2020 | Know the Latest COVID19 Impact Analysis And Strategies of Key Players: Praxair, Cellulis, Cryologics, Cryotherm,...

Recommendation and review posted by Bethany Smith

Researchers discovered that stem cells taken from fat tissues have growth hormones that can work on hair. They used those stem cells to create a new solution that triggers hair regrowth among people with male-pattern baldness.

Androgenetic alopecia or also known as male-pattern baldness or female-pattern baldness is caused by genetics, and hormonal and environmental factors. According to the researchers from Pusan National University Yangsan Hospital in South Korea, it affects about 50% of all men and a similar percentage among women over 50 years old.

The researchers recruited 29 male and nine women patients or 38 people with common baldness to participate in their study. The participants rubbed the new solution into their scalp two times a day. After 16 weeks, they found a significant increase in hair count.

Male-pattern baldness is not a life-threatening condition. However, it can lower one's self-esteem and psychological wellbeing in people with the condition. Some FDA approved medications in the United States to treat hair loss though proven effective, can have side effects like the loss of libido and erectile dysfunction.

Daily Mail reported that scientists discovered the new medication when they found connective tissue let off growth hormones that help cells develop. They examined the stem cells in detail and found that they could activate numerous growth factors that increase the size of the hair follicles.

Researcher Professor Sang Yeoup said that recent studies have shown that the newly developed solution can promote hair growth in both men and women with Androgenetic alopecia. "However, no randomized, placebo-controlled trial in humans has explored the effects and safety of adipose-derived stem cell constituent extract (ADSC-CE) in male pattern baldness," he added.

The participants of their study were middle-aged people with alopecia to identify whether ADSC-CE solutions could work to cure their condition.

Half of the 38 patients being studied were given ADSC-CE solution, and the other half is the placebo solution without the growth hormones. The participants applied a solution- either the experimental or placebo- to their scalps with their fingers. They did it twice a day for 16 weeks.

"At the end of 16 weeks, the group that received the ADSC-CEs had a significant increase in both hair count and follicle diameter," said Young Jin Tak, the senior author of the study. The researchers published their study in the journal Stem Cells Translational Medicine.

Read Also: David Beckham's Case of Missing Hair Sparks Questions on the Best Hair Loss Treatment

Their findings suggest that the ADSC-CE solution can have 'enormous potential' as an alternative to other hair growth solutions currently available as they increase hair density and thickness. The researchers recommend conducting another study with a large and diverse population to confirm the benefits of ADSC-CE on hair growth and explain how mechanisms responsible for the action of ADSC-CE in humans.

According to Anthony Atala, editor-in-chief of STEM CELLS translational medicine and director of the Wake Forest Institute for Regenerative Medicine, the new solution created from adipose tissue cells proves to be both safe and effective. Also, it offers hope to those people suffering from the pattern baldness condition.

Read More: Femininity and Attractiveness: Why Women Feel the Need to Go Hairless

Original post:
Scientists Found New Baldness Cure that Could Trigger Regrowth in Just 4 Months! - Science Times

Recommendation and review posted by Bethany Smith

Global Gene Therapy Products Market analysis report is a historical overview and all-inclusive study on the current & future market of the Healthcare industry. This market study has been analyzed and takes into account the CAGR of the market, valuation, volume, revenue including historical and forecast, sales (current and future), and other significant factors related to the global market. Gene Therapy Products Market business document puts forward an in-depth assessment of each crucial aspect of the worldwide market that relates to the market size, market share, market growth factor, key vendors, revenue, top regions, industry trends, product demand, sales volume, capacity, cost structure & expansion in the market.

Get ExclusiveSample Copy of This Report Herehttps://www.databridgemarketresearch.com/request-a-sample?dbmr=global-gene-therapy-products-market

Global gene therapy products market is set to witness a substantial CAGR in the forecast period of 2019- 2026. The report contains data of the base year 2018 and historic year 2017. Rising cancer cases and unused potential for emerging markets are the major factors for the growth of this market.

Few of the major competitors currently working in the globalgene therapy products marketareAdaptimmune., Anchiano Therapeutics, bluebird bio, Inc., CELGENE CORPORATION, GlaxoSmithKline plc., Merck KGaA, Novartis AG, Achieve Life Sciences, Inc., Spark Therapeutics, Inc., Abeona Therapeutics, Inc, Adverum, agtc, Arbutus Biopharma, Audentes Therapeutics, AveXis, Inc., CRISPR Therapeutics, Intellia Therapeutics, Inc and Gilead Sciences,Inc. among others.

Market Definition:Global Gene Therapy Products Market

Gene therapy or human gene therapy is a process which is used to modify gene for the treatment of any disease. Plasmid DNA, bacterial vector, human gene editing technology and viral vectors are some of the most common type of gene therapy products. The main aim of the gene therapy is to replace the dysfunctional genes. Somatic and germline are some of the most common type of the gene therapy.

Complete report on Global Gene Therapy Product Market Research Report 2019-2026 spread across 350 Pages, profiling Top companies and supports with tables and figures

Segmentation: Global Gene Therapy Products Market

Gene Therapy Products Market : By Product

Gene Therapy Products Market : By Application

Gene Therapy Products Market : ByGeography

Read Complete Details with TOC Herehttps://www.databridgemarketresearch.com/toc?dbmr=global-gene-therapy-products-market

Key Developments in the Gene Therapy Products Market:

Gene Therapy Products Market Drivers

Gene Therapy Products Market Restraints

Competitive Analysis: Gene Therapy Products Market

Global gene therapy products market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of gene therapy products market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key questions answered in the report :-

To get this report at an attractive cost, click herehttps://www.databridgemarketresearch.com/speak-to-analyst?dbmr=global-gene-therapy-products-market

About Data Bridge Market Research:

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475 Mail:[emailprotected]

View original post here:
Gene Therapy Products Market (Covid 19 Analysis) By 2026 | Competitive Outlook By Adverum, agtc, Arbutus Biopharma, Audentes Therapeutics, AveXis Inc....

Recommendation and review posted by Bethany Smith

The report highlights the key growth drivers and trends that will contribute to the growth momentum of the market. The report provides an incisive analysis of the growth dynamics and quantitative assessment of the revenue potential in various regions and across key products, application/end-use industry, and technology segments. It provides a comprehensive insight into the shares and sizes of the various segments in each year of the forecast period. The assessment of the growth dynamics in the Gene Therapy Market cover the year-over-year growth of key geographies, and the incremental opportunities in numerous key countries.

Get Sample Copy of this Report https://www.factmr.com/connectus/sample?flag=S&rep_id=4648

The authors of the report have made a rigorous assessment of various industry-specific trends and analysis of the macroeconomic environment prevailing in various regions around the world.

A comprehensive evaluation of recent investments by top players in the gene therapy market helps identify major research and development initiatives in the gene therapy markets. The various assessments on the competitive landscape focus on the intensity of competition, entry barriers, PESTLE analysis, and key winning imperatives. The readers can further find pertinent information on the recent market developments such as divestments, entry of players from different industries, licensing deals, and long-term partnerships to consolidate shares by top players.

Key companies profiled in the study are:

The study further identifies major manufacturing trends, technologies that will be commercialized, and

The detailed market estimations cover the following:

How will be insights and market estimations provided in the Fact.MR report on the gene therapy market make a difference:

The gene therapy market is segmented on the basis of geography into:

On the basis of product types,

A Customization of this Report is Available upon Request https://www.factmr.com/connectus/sample?flag=RC&rep_id=4648

About Fact.MR

Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; thats why we publish multi-industry global, regional, and country-specific research reports.

Contact:

Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers, Dubai, United Arab Emirates

MARKET ACCESS DMCC Initiative

Email: sales@factmr.com

Web: https://www.factmr.com/

Read the original here:
Gene Therapy Market Dynamics, Forecast, Analysis and Supply Demand 2020 2026 - The Cloud Tribune

Recommendation and review posted by Bethany Smith

New statistical research on Gene Therapy Technologies Market 2020 will show you the latest industry insights on future trends, product, and service analysis, allowing you to penetrate deeply into the keyword market with high profitability.

The Gene Therapy Technologies Market Report provides an in-depth analysis of the entire market. This report focuses on mainstream key players, production details, their applications, then analyzes global and major regional market potentials and benefits, opportunities, challenges, constraints, and risks.

There are a number of major competitive biotech companies that investigate the SARSs-Cov-2 genome and prepare a survival vaccine for it. Compared to the response rate to SARs/MERs, biotech organizations are investigating SARs-Cov-2 at an unprecedented rate, and a significant amount of funds are being put into R&D. For this reason, the report describes Covid19 as a major market contributor.

This report sample includes: Brief Introduction to the research report, Table of Contents (Scope covered as a part of the study), Top players in the market, Research framework (Structure of This Report), Research methodology adopted by Worldwide Market Reports.

Request a Copy of the Sample

The Top Players Covered in Gene Therapy Technologies Market Are: Bluebird bio, Adaptimmune, GlaxoSmithKline, Merck, Celgene, Shanghai Sunway Biotech, BioCancell, Shenzhen SiBiono GeneTech, SynerGene Therapeutics, OncoGenex Pharmaceuticals, Genelux Corporation, Cell Genesys, Advantagene, GenVec, BioCancell, Celgene, Epeius Biotechnologies, Introgen Therapeutics, Ziopharm Oncology

Gene Therapy Technologies Market Outlook:

The Global Gene Therapy Technologies Market Report gives an exclusive coverage provided for market drivers, challenges, and opportunities for country-level markets in each regional segment. This report consists of a competitive analysis of the key players operating in the market and covers in-depth data related to the markets competitive environment, recent strategies and products to support or influence the market over the next few years.

Market Drivers and the Risks Associated With the Gene Therapy Technologies Market:

The Gene Therapy Technologies Market is characterized by several key factors, each of which tends to play a decisive role in the growing market. Product growth has doubled with the smooth availability of a customer base that helps companies thrive around the world. On the other hand, the presence of a dynamic supply chain helped the company grow exponentially. So, with respect to the increase in Gene Therapy Technologies Market opportunities, Gene Therapy Technologies face serious dissatisfaction in all respects.

Some Fundamental Parameters Included in the Report:

Buy This Complete Business Report: Access Insightful Study With Over 150+ Pages, List of Tables and Figures, Profiling 20+ Companies.

The Main Geographical Regions and Markets of the Gene Therapy Technologies Market:

If you look more closely at that region, the market is concentrated and what matters inside the file is to highlight Europe, the Middle East, and Africa, Asia Pacific, Latin America, and North America. These areas studied the intertwined traits and various possibilities, along with the prospects that could ultimately benefit the market.

Gene Therapy Technologies Market Report Covers Following Questions:

Customization Service of the Report

Worldwide Market Reports provide reports that can be customized upon request. This report can be personalized to suit your needs. Please contact the research team so that you can receive a report tailored to your needs.

Quick Enquiryoption enables you to share your queries, in advance to procure the report. Kindly fill the form, and one of our consultants would get in touch with you to discuss the queries, and would address them.

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends.

Continue reading here:
Gene Therapy Technologies Market: Comprehensive Study of Leading Key Players Explores Huge Growth in Future: Bluebird bio, Adaptimmune,...

Recommendation and review posted by Bethany Smith

The research study on Global Personalized Gene Therapy Treatment market 2019 presents an extensive analysis of current Personalized Gene Therapy Treatment market size, drivers, trends, opportunities, challenges, as well as key Personalized Gene Therapy Treatment market segments. Further, it explains various definitions and classification of the Personalized Gene Therapy Treatment industry, applications, and chain structure.In continuation of this data, the Personalized Gene Therapy Treatment report covers various marketing strategies followed by key players and distributors. Also explains Personalized Gene Therapy Treatment marketing channels, potential buyers and development history. The intent of global Personalized Gene Therapy Treatment research report is to depict the information to the user regarding Personalized Gene Therapy Treatment market forecast and dynamics for the upcoming years. The Personalized Gene Therapy Treatment study lists the essential elements which influence the growth of Personalized Gene Therapy Treatment industry. Long-term evaluation of the worldwide Personalized Gene Therapy Treatment market share from diverse countries and regions is roofed within the Personalized Gene Therapy Treatment report. Additionally, includes Personalized Gene Therapy Treatment type wise and application wise consumption figures.

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10225585

After the basic information, the global Personalized Gene Therapy Treatment Market study sheds light on the Personalized Gene Therapy Treatment technological evolution, tie-ups, acquisition, innovative Personalized Gene Therapy Treatment business approach, new launches and Personalized Gene Therapy Treatment revenue. In addition, the Personalized Gene Therapy Treatment industry growth in distinct regions and Personalized Gene Therapy Treatment R;D status are enclosed within the report.The Personalized Gene Therapy Treatment study also incorporates new investment feasibility analysis of Personalized Gene Therapy Treatment. Together with strategically analyzing the key micro markets, the report also focuses on industry-specific drivers, restraints, opportunities, and challenges in the Personalized Gene Therapy Treatment market.

Global Personalized Gene Therapy Treatment Market Segmentation 2019: Personalized Gene Therapy TreatmentThe study also classifies the entire Personalized Gene Therapy Treatment market on basis of leading manufacturers, different types, various applications and diverse geographical regions. Overall Personalized Gene Therapy Treatment market is characterized by the existence of well-known global and regional Personalized Gene Therapy Treatment vendors. These established Personalized Gene Therapy Treatment players have huge essential resources and funds for Personalized Gene Therapy Treatment research as well as developmental activities. Also, the Personalized Gene Therapy Treatment manufacturers focusing on the development of new Personalized Gene Therapy Treatment technologies and feedstock. In fact, this will enhance the competitive scenario of the Personalized Gene Therapy Treatment industry.

The Leading Players involved in global Personalized Gene Therapy Treatment market are:

By Therapy (Targeted Treatments and Pharmacogenomics),By Application (Breast Cancer, Brain Cancer, Colorectal Cancer, Certain Childhood Cancers, Gastrointestinal Stromal Tumor, Kidney Cancer, Leukemia, Lymphoma, Melanoma, Lung Cancer, and Multiple Myeloma)By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10225585

Worldwide Personalized Gene Therapy Treatment Market Different Analysis:Competitors Review of Personalized Gene Therapy Treatment Market: Report presents the competitive landscape scenario seen among top Personalized Gene Therapy Treatment players, their company profile, revenue, sales, business tactics and forecast Personalized Gene Therapy Treatment industry situations. Production Review of Personalized Gene Therapy Treatment Market: It illustrates the production volume, capacity with respect to major Personalized Gene Therapy Treatment regions, application, type, and the price. Sales Margin and Revenue Accumulation Review of Personalized Gene Therapy Treatment Market: Eventually explains sales margin and revenue accumulation based on key regions, price, revenue, and Personalized Gene Therapy Treatment target consumer. Supply and Demand Review of Personalized Gene Therapy Treatment Market: Coupled with sales margin, the report depicts the supply and demand seen in major regions, among key players and for every Personalized Gene Therapy Treatment product type. Also interprets the Personalized Gene Therapy Treatment import/export scenario. Other key reviews of Personalized Gene Therapy Treatment Market: Apart from the above information, correspondingly covers the company website, number of employees, contact details of major Personalized Gene Therapy Treatment players, potential consumers and suppliers. Also, the strengths, opportunities, Personalized Gene Therapy Treatment market driving forces and market restraints are studied in this report.

Highlights of Global Personalized Gene Therapy Treatment Market Report:* This report provides in detail analysis of the Personalized Gene Therapy Treatment and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2019 ; 2029. * It also elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for world Personalized Gene Therapy Treatment market. * This study also provides key insights about Personalized Gene Therapy Treatment market drivers, restraints, opportunities, new product launches, approvals, regional outlook, and competitive strategies adopted by the leading Personalized Gene Therapy Treatment players. * It profiles leading players in the worldwide Personalized Gene Therapy Treatment market based on the following parameters ; company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans. * Insights from Personalized Gene Therapy Treatment report would allow marketers and management authorities of companies to make an informed decision with respect to their future product launches, market expansion, and Personalized Gene Therapy Treatment marketing tactics. * The world Personalized Gene Therapy Treatment industry report caters to various stakeholders in Personalized Gene Therapy Treatment market. That includes investors, device manufacturers, distributors and suppliers for Personalized Gene Therapy Treatment equipment. Especially incorporates government organizations, Personalized Gene Therapy Treatment research and consulting firms, new entrants, and financial analysts. *Various strategy matrices used in analyzing the Personalized Gene Therapy Treatment market would provide stakeholders vital inputs to make strategic decisions accordingly.

Global Personalized Gene Therapy Treatment Market Report Provides Comprehensive Analysis of Following: ; Personalized Gene Therapy Treatment Market segments and sub-segments ; Industry size ; Personalized Gene Therapy Treatment shares ; Personalized Gene Therapy Treatment Market trends and dynamics ; Market Drivers and Personalized Gene Therapy Treatment Opportunities ; Supply and demand of world Personalized Gene Therapy Treatment industry ; Technological inventions in Personalized Gene Therapy Treatment trade ; Personalized Gene Therapy Treatment Marketing Channel Development Trend ; Global Personalized Gene Therapy Treatment Industry Positioning ; Pricing and Brand Strategy ; Distributors/Traders List enclosed in Positioning Personalized Gene Therapy Treatment Market.

Request For Full Report:https://www.kennethresearch.com/sample-request-10225585

Moreover, the report organizes to provide essential information on current and future Personalized Gene Therapy Treatment market movements, organizational needs and Personalized Gene Therapy Treatment industrial innovations. Additionally, the complete Personalized Gene Therapy Treatment report helps the new aspirants to inspect the forthcoming opportunities in the Personalized Gene Therapy Treatment industry. Investors will get a clear idea of the dominant Personalized Gene Therapy Treatment players and their future forecasts.

About Kenneth Research:

Kenneth Research provides market research reports to different individuals, industries, associations and organizations with an aim of helping them to take prominent decisions. Our research library comprises of more than 10,000 research reports provided by more than 15 market research publishers across different industries. Our collection of market research solutions covers both macro level as well as micro level categories with relevant and suitable market research titles. As a global market research reselling firm, Kenneth Research provides significant analysis on various markets with pure business intelligence and consulting services on different industries across the globe. In addition to that, our internal research team always keep a track on the international and domestic market for any economic changes impacting the products demand, growth and opportunities for new and existing players.

Contact Us

Kenneth ResearchEmail: [emailprotected]Phone: +1 313 462 0609

The rest is here:
Personalized Gene Therapy Treatment Market Overview By Share, Size, Industry Players, Revenue And Product Demand Forecast Till 2029 - Jewish Life News

Recommendation and review posted by Bethany Smith

UpMarketResearch report titled Global Cancer Gene Therapy Market provides detailed information and overview about the key influential factors required to make well informed business decision. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. Our data has been culled out by our team of experts who have curated the report, considering market-relevant information. This report provides latest insights about the markets drivers, restraints, opportunities, and trends. It also discusses the growth and trends of various segments and the market in various regions.

Request Free Sample Report of Cancer Gene Therapy Market Report @ https://www.upmarketresearch.com/home/requested_sample/42057

Cancer Gene Therapy Market Report Includes:

For More Information on This Report Visit @ https://www.upmarketresearch.com/home/enquiry_before_buying/42057

By Product Types:Insertion of new genes into the bodyOther

The report is further broken down into various segments such as product types, applications, and regions.

By Applications:HospitalsDiagnostic CentresDrug ManufacturersResearch Institutes

Our analysts drafted the report by gathering information through primary (through surveys and interviews) and secondary (included industry body databases, reputable paid sources, and trade journals) methods of data collection. The report encompasses an exhaustive qualitative and quantitative evaluation.

The study includes growth trends, micro- and macro-economic indicators, and regulations and governmental policies.

By Regions:Asia Pacific (China, Japan, India, and Rest of Asia Pacific)Europe (Germany, the UK, France, and Rest of Europe)North America (the US, Mexico, and Canada)Latin America (Brazil and Rest of Latin America)Middle East & Africa (GCC Countries and Rest of Middle East & Africa)

The Cancer Gene Therapy Market Report Covers the Following Companies:Cell GenesysAdvantageneGenVecBioCancellCelgene and Epeius BiotechnologiesIntrogen TherapeuticsZIOPHARM OncologyMultiVirShenzhen SiBiono GeneTech

The subject matter experts analyzed various companies to understand the products and/services relevant to the market. The report includes information such as gross revenue, production and consumption, average product price, and market shares of key players. Other factors such as competitive analysis and trends, mergers & acquisitions, and expansion strategies have been included in the report. This will enable the existing competitors and new entrants understand the competitive scenario to plan future strategies.

To Purchase This Report: https://www.upmarketresearch.com/buy/cancer-gene-therapy-market-research

The Report Provides:

The Cancer Gene Therapy Market Report Addresses the Following Queries:

For Best Discount on Purchasing this Report Visit https://www.upmarketresearch.com/home/request_for_discount/42057

About UpMarketResearch:UpMarketResearch (https://www.upmarketresearch.com) is a leading distributor of market research report with more than 800+ global clients. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.Contact Info UpMarketResearchName Alex MathewsEmail [emailprotected]Website https://www.upmarketresearch.comAddress 500 East E Street, Ontario, CA 91764, United States.

Continued here:
Global Cancer Gene Therapy Market Scope and Price Analysis of Top Manufacturers Profiles 2019-2025 - Cole of Duty

Recommendation and review posted by Bethany Smith

Other

The report is a compilation of different studies, including regional analysis where leading regional Gene Therapy markets are comprehensive studied by market experts. Both developed and developing regions and countries are covered in the report for a 360-degree geographic analysis of the Gene Therapy market. The regional analysis section helps readers to become familiar with the growth patterns of important regional Gene Therapy markets. It also provides information on lucrative opportunities available in key regional Gene Therapy markets.

Ask For Discounts, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=304727&utm_source=COD&utm_medium=888

Table of Content

1 Introduction of Gene Therapy Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Gene Therapy Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Gene Therapy Market, By Deployment Model

5.1 Overview

6 Gene Therapy Market, By Solution

6.1 Overview

7 Gene Therapy Market, By Vertical

7.1 Overview

8 Gene Therapy Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Gene Therapy Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Get Complete Report

@ https://www.marketresearchintellect.com/need-customization/?rid=304727&utm_source=COD&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Gene Therapy Market Size, Gene Therapy Market Trends, Gene Therapy Market Growth, Gene Therapy Market Forecast, Gene Therapy Market Analysis Sarkari result, Government Jobs, Sarkari naukri, NMK, Majhi Naukri,

Continue reading here:
Gene Therapy Market Development, Trends, Key Driven Factors, Segmentation And Forecast to 2020-2026 - Cole of Duty

Recommendation and review posted by Bethany Smith

A perfect mix of quantitative & qualitative Gene Therapy for Age-related Macular Degenerationmarket information highlighting developments, industry challenges that competitors are facing along with gaps and opportunities available and would trend in Gene Therapy for Age-related Macular Degenerationmarket. The study bridges the historical data from 2014 to 2019 and estimated until 2025.

The Gene Therapy for Age-related Macular DegenerationMarket report also provides the market impact and new opportunities created due to the COVID19/CORONA Virus Catastrophe The total market is further divided by company, by country, and by application/types for the competitive landscape analysis. The report then estimates 2020-2025 market development trends of Gene Therapy for Age-related Macular DegenerationIndustry.

Downlaod Sample ToC to understand the CORONA Virus/COVID19 impact and be smart in redefining business strategies. https://inforgrowth.com/CovidImpact-Request/6321856/gene-therapy-for-age-related-macular-degeneration-

The Top players are RetroSense Therapeutics, REGENXBIO, AGTC, .

Market Segmentation:

Gene Therapy for Age-related Macular Degeneration Market is analyzed by types like Subretinal, Intravitreal, Unspecified

On the basis of the end users/applications, Monotherapy, Combination Therapy

Download Free Sample PDF along with few company profileshttps://inforgrowth.com/sample-request/6321856/gene-therapy-for-age-related-macular-degeneration-

Be the first to knock the door showing the potential that Gene Therapy for Age-related Macular Degenerationmarket is holding in it. Uncover the Gaps and Opportunities to derive the most relevant insights from our research document to gain market size.

A major chunk of this Global Gene Therapy for Age-related Macular DegenerationMarket research report is talking about some significant approaches for enhancing the performance of the companies. Marketing strategies and different channels have been listed here. Collectively, it gives more focus on changing rules, regulations, and policies of governments. It will help to both established and new startups of the market.

The study objectives of this report are:To analyze global Gene Therapy for Age-related Macular Degenerationstatus, future forecast, growth opportunity, key market, and key players.To present the Gene Therapy for Age-related Macular Degenerationdevelopment in the United States, Europe, and China.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by product type, market, and key regions.

Get Special Discount Up To 50%, https://inforgrowth.com/discount/6321856/gene-therapy-for-age-related-macular-degeneration-

Major Points from Table of Contents

1 Gene Therapy for Age-related Macular Degeneration Gene Therapy for Age-related Macular Degeneration Market Overview2 Gene Therapy for Age-related Macular Degeneration Market Competition by Manufacturers3 Production Capacity by Region4 Global Gene Therapy for Age-related Macular Degeneration Market by Regions5 Production, Revenue, Price Trend by Type6 Global Gene Therapy for Age-related Macular Degeneration Market Analysis by Application7 Company Profiles and Key Figures in Gene Therapy for Age-related Macular Degeneration Business8 Gene Therapy for Age-related Macular Degeneration Manufacturing Cost Analysis9 Marketing Channel, Distributors and Customers10 Market Dynamics11 Production and Supply Forecast12 Consumption and Demand Forecast13 Forecast by Type and by Application (2021-2026)14 Research Finding and Conclusion15 Methodology and Data Source.

ENQUIRE MORE ABOUT THIS REPORT AT https://inforgrowth.com/enquiry/6321856/gene-therapy-for-age-related-macular-degeneration-

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USAContact Name: Rohan S.Email:[emailprotected]Phone: +1-909-329-2808UK: +44 (203) 743 1898Website: http://www.inforgrowth.com

Go here to read the rest:
Latest News 2020: Gene Therapy for Age-related Macular Degeneration Market by Coronavirus-COVID19 Impact Analysis With Top Manufacturers Analysis |...

Recommendation and review posted by Bethany Smith

MINNEAPOLIS & EL SEGUNDO, Calif.--(BUSINESS WIRE)--Be The Match BioTherapies, an organization offering solutions for companies developing and commercializing cell and gene therapies, and NantKwest (Nasdaq: NK), a next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the immune system using natural killer (NK) cells to treat cancer and infectious diseases, today announced an agreement through which Be The Match BioTherapies is providing donor material for a NantKwest Phase 1b clinical trial to address acute respiratory distress syndrome (ARDS), one of the primary causes of COVID-19 deaths.

The agreement combines Be The Match BioTherapies ability to provide high-quality cellular source material from the worlds largest registry of volunteer donors with NantKwests capabilities in manufacturing off-the-shelf cell therapies. NantKwests allogeneic cell therapy is derived from human bone marrow and designed to treat the ARDS that results from severe COVID-19 cases. The therapy, called BM-Allo.MSC, uses mesenchymal stem cells (MSCs), multipotent progenitor cells known to have immunomodulatory properties, to reduce the lung inflammation associated with ARDS. Similar work in Europe with allogeneic MSC products in patients with COVID-19 and ARDS has demonstrated safety and efficacy in reducing inflammatory processes.

NantKwest recently announced FDA authorization of its investigational new drug (IND) application for BM-Allo.MSC and is moving rapidly to initiate a Phase 1b trial in patients with severe COVID-19. To expedite trial initiation, Be The Match BioTherapies is providing cryopreserved donor stem cell material from the Be The Match BioBank, a program of the National Marrow Donor Program/Be The Match. The accelerated access to material, combined with NantKwests scalable manufacturing processes, will allow for rapid distribution of BM-Allo.MSC to patients in need.

There is an immediate need for COVID-19 therapies across all stages of the disease, including for patients with ARDS, which is one of the most critical conditions caused by COVID-19, said Patrick Soon-Shiong, MD, Chairman and Chief Executive Officer of NantKwest. Thanks to the quality source material provided by Be The Match BioTherapies, we are prepared to rapidly scale manufacturing of this much-needed therapy, potentially saving numerous patients lives.

Through our teams unparalleled ability to identify, source and deliver high-quality donor material we have the opportunity to support the advancement of a cell therapy with potential to change the world. We are proud to partner with NantKwest to support our mission to save lives through cellular therapy and continue to make a difference for critically ill patients around the globe, said Chris McClain, Senior Vice President, Sales and New Business Development at Be The Match BioTherapies.

About Be The Match BioTherapies

Be The Match BioTherapies is the only cell and gene therapy solutions provider with customizable services to support the end-to-end cell therapy supply chain. Backed by the industry-leading experience of the National Marrow Donor Program (NMDP)/Be The Match, and a research partnership with the CIBMTR (Center for International Blood and Marrow Transplant Research), the organization designs solutions that advance the development of cell and gene therapies across the globe.

Be The Match BioTherapies is dedicated to accelerating patient access to life-saving cell and gene therapies by providing high-quality cellular source material from the Be The Match Registry, the worlds largest and most diverse registry of more than 22 million potential blood stem cell donors. Through established relationships with apheresis, marrow collection and transplant centers worldwide, the organization develops, onboards, trains and manages expansive collection networks to advance cell therapies. Be The Match BioTherapies uses proven infrastructure consisting of regulatory compliance and managed logistics experts, as well as cell therapy supply chain case managers to successfully transport and deliver regulatory compliant life-saving therapies across the globe. Through the CIBMTR, Be The Match BioTherapies extends services beyond the cell therapy supply chain to include long-term follow-up tracking for the first two FDA-approved CAR-T therapies.

For more information, visit http://www.BeTheMatchBioTherapies.com or follow Be The Match BioTherapies on LinkedIn or Twitter at @BTMBioTherapies.

About NantKwest

NantKwest (Nasdaq: NK) is an innovative, clinical-stage immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and virally-induced infectious diseases. NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safety of these optimized, activated NK cellsas well as their activity against a broad range of cancershas been tested in Phase I clinical trials in Canada and Europe, as well as in multiple Phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwests goal is to transform medicine by delivering living drugs-in-a-bag and bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies. For more information, please visit http://www.nantkwest.com.

Read more from the original source:
Be The Match BioTherapies and NantKwest Announce Collaboration to Accelerate Development of Cell Therapy to Prevent COVID-19 Deaths - Business Wire

Recommendation and review posted by Bethany Smith

(MENAFN - eSherpa Market Reports) Global Gene Therapy Market trend report 2020 highlights the Impact of COVID-19 on Gene Therapy Market. The report defines market risks, business portfolio, market share, revenue generation, the latest research and development, and market expert perspectives. It comprises brief information about the segments, as well as insightful research on Porter's five forces analysis and SWOT analysis.

Then the market is an analysis based on top industry manufacturers, countries, product types, and key applications. based on segments by manufacturers, this report focuses on the sales, price of each type, the average price, revenue, and market share, for key manufacturers.

Get Free Sample PDF Copy (including COVID19 Impact Analysis, full TOC, Tables, and Figures) of Gene Therapy Market Report @ https://www.esherpamarketreports.com/request-sample/es-408437/?utm_source=MENAFN

Key Businesses Segmentation of Gene Therapy Market:

By Types, the Gene Therapy Market can be Splits into:

Gene Induced ImmunotherapyOncolytic VirotherapyGene TransferBy Applications, the Gene Therapy Market can be Splits into:

HospitalsDiagnostics CentersResearch InstitutesList of Top Key Players of Gene Therapy Market:

Adaptimmune, GlaxoSmithKline, Bluebird bio, Merck, Celgene, Shanghai Sunway Biotech, BioCancell, Shenzhen SiBiono GeneTech, SynerGene Therapeutics, OncoGenex Pharmaceuticals, Genelux Corporation, Cell Genesys, Advantagene, GenVec, BioCancellThe study objectives of Gene Therapy Market report are:

To research the Gene Therapy for individual growth trends and their contribution to the entire market.To analyze and study the worldwide Gene Therapy capacity, production, value, consumption, status (2014-2019) and forecast (2020-2024);To strategically profile the key players and completely analyze their growth strategies.To identify significant trends and factors affecting market growth.To define and forecast the market by type, application and region.To project the consumption of Gene Therapy submarkets, for key regions

Enquire before purchasing this report @ https://www.esherpamarketreports.com/pre-order-enquiry/es-408437?utm_source=MENAFN

The Gene Therapy Market Report has answers to all your questions such as:

What are the opportunities which will affect the expansion of the market?What is the structure of the Gene Therapy market in region 1?What are the various distribution channels adopted by market players within the Gene Therapy market?Who are the most famous players within the Gene Therapy market?What is going to be the estimation of cost and profit?

Reasons To Buy:

Market forecast for a minimum of 5 years for all the segments, sub-segments in various countries and regionsTop competitors using forecast data and also the drivers and trends shaping the market.Benchmark performance against key competitors.Strategic support in key business segments based on market valuationsAccurate and complete study of the Gene Therapy market with the help of SWOT analysis, and opportunity evaluation.

Purchase this Report with Full Access @ https://www.esherpamarketreports.com/purchase/es-408437/?utm_source=MENAFN

Gene Therapy Market TOC Covers the Following Points:

Section 1 Gene Therapy Product DefinitionSection 2 Global Gene Therapy Market Manufacturer Share and Market Overview2.1 Global Manufacturer Gene Therapy Shipments2.2 Global Manufacturer Gene Therapy Business Revenue2.3 Global Gene Therapy Market OverviewSection 3 Manufacturer Gene Therapy Business IntroductionSection 4 Global Gene Therapy Market Segmentation (Region Level)Section 5 Global Gene Therapy Market Segmentation (Product Type Level)5.1 Global Gene Therapy Market Segmentation (Product Type Level) Market Size 2014-20195.2 Different Gene Therapy Product Type Price 2014-20195.3 Global Gene Therapy Market Segmentation (Product Type Level) AnalysisSection 6 Global Gene Therapy Market Segmentation (Industry Level)6.1 Global Gene Therapy Market Segmentation (Industry Level) Market Size 2014-20196.2 Different Industry Price 2014-20196.3 Global Gene Therapy Market Segmentation (Industry Level) AnalysisSection 7 Global Gene Therapy Market Segmentation (Channel Level)7.1 Global Gene Therapy Market Segmentation (Channel Level) Sales Volume and Share 2014-20197.2 Global Gene Therapy Market Segmentation (Channel Level) AnalysisSection 8 Gene Therapy Market Forecast 2019-20248.1 Gene Therapy Segmentation Market Forecast (Region Level)8.2 Gene Therapy Segmentation Market Forecast (Product Type Level)8.3 Gene Therapy Segmentation Market Forecast (Industry Level)8.4 Gene Therapy Segmentation Market Forecast (Channel Level)Section 9 Gene Therapy Segmentation Product TypeSection 10 Gene Therapy Segmentation IndustrySection 11 Gene Therapy Cost of Production Analysis11.1 Raw Material Cost Analysis11.2 Technology Cost Analysis11.3 Labor Cost Analysis11.4 Cost Overview.And More

Contact Us:

Name: Jason George

Email:

Call : USA: +1 408 757 0510

Organization: eSherpa Market Reports

MENAFN19052020007010847ID1100186734

The rest is here:
COVID-19: RESPONDING TO THE BUSINESS IMPACTS OF Gene Therapy MARKET 2019 TRENDS, SIZE, SEGMENTS, EMERGING TECHNOLOGIES AND INDUSTRY GROWTH BY...

Recommendation and review posted by Bethany Smith

SEATTLE, May 19, 2020 (GLOBE NEWSWIRE) -- Increasing incidence of antimicrobial-resistance is expected to drive growth of the bacteriophage therapy market during the forecast period. For instance, according to Centers for Disease Control and Prevention (CDC), around 2 million people suffer from antibiotic-resistant infection, and at least 23,000 people die each year in the U.S.

Rising funding for research and development of bacteriophage therapies is expected to drive the market growth. For instance, in August 2018, Phagomed Biopharma Gmbh. announced that their alternative therapies to combat antibiotic-resistant bacteria, has obtained grants worth US$ 4.67 million for developing virus(phage) based therapies against bacterial infections. The grant will be used to continue pre-clinical development of three drug candidates.

Read Report Summary @ https://www.coherentmarketinsights.com/market-insight/bacteriophages-therapy-market-2752

Increasing government funding is supporting phage therapy manufacturers to develop innovative approach in order to reduce incidence of antimicrobial-resistant infections is expected to propel the market growth. For instance, in January 2016, National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health, has awarded US$ 5 million for 24 research projects to develop non-traditional therapeutics such as bacteriophage or phage therapy and others therapies for the treatment of bacterial infections

Furthermore, increasing acquisitions and partnership agreements by players are expected to propel the market growth over the forecast period. For instance, in July 2019, Pherecydes Pharma entered a collaborative agreement with France-based, Bioaster Technology Research Institute (TRI) for microbiology and infectious diseases, to explore the use of phage therapy for treating complicated urinary tract infections. Under this collaboration, Pherecydes Pharma and Bioaster initiated PhagUTI project.

Request for Sample PDF copy @ https://www.coherentmarketinsights.com/insight/request-sample/2752

Key Market Takeaways:

Key players operating in the global bacteriophage therapy market include

Armata Pharmaceuticals, Inc., Eliava Biopreparations Ltd., Pherecydes Pharma, Intralytix, Inc., Phagelux Inc., Nextbiotics, InnoPhage, Ltd, Locus Biosciences, Inc., TechnoPhage, Eligo Bioscience SA, Phagomed Biopharma GmbH., PhagePro, Inc., Adaptive Phage Therapeutics, Inc., EnBiotix, Inc., Intodeworld, Inc., BiomX Ltd., Phi Therapeutics, Fixed-phage Ltd., Micreos BV, and ContraFect Corporation.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/2752

Market Segmentation:

Related Topics:

GLYCOBIOLOGY MARKET

Glycobiology involves study of structural aspects, biosynthesis, and biology of polysaccharides and how they function in an organism. Study of glycobiology has variety of application in areas such as drug discovery and development, diagnostic applications, therapeutic application, and industrial applications.

Read more @ https://www.coherentmarketinsights.com/market-insight/glycobiology-market-3639

VIRAL VECTOR AND PLASMID DNA TESTING SERVICES MARKET

Viral vectors are the best approach used in the gene therapies and therefore, testing services are the key factors for the timely development of viral vector-based therapies. Viral vector characterization plays an important role for orthogonal analytical approaches. The characterization is significant through the regulatory perspective, which include product safety, identity, purity, and potency.

Read more @ https://www.coherentmarketinsights.com/market-insight/viral-vector-and-plasmid-dna-testing-services-market-3637

GMP CELL BANKING SERVICES MARKET

GMP cell banking services is termed as the storing of cells of specific genome for the purpose of future use in a product or medicinal needs. Different types of cell lines stored in cell banks constitute of mammalian cells, microbial cells, insect cell lines, yeast cells, avian cells, and stem cells.

Read more @ https://www.coherentmarketinsights.com/market-insight/gmp-cell-banking-services-market-3634

Go here to read the rest:
Bacteriophage Therapy Market to grow at a significant rate during 2020-2027, owing to rising prevalence of antibiotic resistant infection Coherent...

Recommendation and review posted by Bethany Smith

DUBLIN, May 19, 2020 /PRNewswire/ -- The "Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics" report has been added to ResearchAndMarkets.com's offering.

Blood-Brain Barrier (BBB) Market, 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics (2nd Edition) [based on Receptor Mediated Transcytosis, Trojan Horse, and Nanoparticle based Approaches] features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of BBB penetration technologies and affiliated drugs, over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for BBB penetration technologies and affiliated therapeutics, over the next decade. Based on likely licensing deal structures and agreements that are expected to be inked in the foreseen future, we have provided an informed estimate of the evolution of the market for the period 2020-2030. In addition, we have provided information on (potential) sales-based revenues generated by BBB penetrant drugs that are currently in late stages of development for the treatment of different CNS disorders, based on parameters, such as target consumer segments, likely adoption rates, expected pricing and associated risk-adjustment sales opportunity.

The report also features the likely distribution of the current and forecasted opportunity across:

Market Summary and Insights

According to a study conducted by the World Health Organization (WHO), diseases that affect the central nervous system (CNS), such as Alzheimer's disease, brain cancer, multiple sclerosis. Parkinson's disease and stroke, are characterized by a significant unmet need for effective treatment options. In 2019, it was reported that nearly 1.5 billion people suffer from some form of disorder affecting the CNS across the globe. In fact, the incidence of CNS disorders is anticipated to increase by 12% by 2030. In 2019, nearly 5.8 million Americans were reported to have been diagnosed with Alzheimer's disease.

Similarly, Parkinson's disease was estimated to affect nearly one million people in America, with approximately 60,000 new patients being diagnosed every year. Further, experts believe that there is a critical relationship between recent pandemic of novel Coronavirus (COVID-19) and the cardiovascular and cerebrovascular systems. People suffering from certain CNS complications are at a relatively higher risk of COVID-19 infection due to a compromised immune system.

It is estimated that CNS disorders are responsible for a healthcare burden of nearly USD 2 trillion, in the US and Europe. Developing viable therapies against the aforementioned clinical conditions is largely complicated due to the elusive blood-brain barrier (BBB), a selectively permeable structure, which is very effective in preventing the entry of foreign substances, including drugs, into the brain. It has been reported that over 1,000 currently available / under development drugs targeting CNS disorders do not have the potential to target specific brain receptors responsible for the disease progression due to the hindrance by the BBB. Considering the serious physical, cognitive and psychosocial consequences that such indications have on patients, coupled to the alarming increase in their global prevalence, there is an urgent need for novel and effective treatment options that can cross the BBB.

Over time, extensive R&D efforts have resulted in the development of a number of versatile BBB penetration technologies. These technologies have been designed either to externally alter the permeability of the BBB or augment the BBB penetrating capabilities of compatible pharmacological interventions. As a result, presently, there is a lot of enthusiasm within the medical science community related to these technologies.

The growing interest in this field is also evident in the fact that over 1,200 modern scientific articles have been published (as observed on NCBI's PubMed portal) over the last three years alone. However, it is worth mentioning that there are currently no approved BBB penetrating drugs available in the market. Currently, this niche market is driven by technology licensing activity, with drug developers collaborating with platform providers to grow their respective therapeutic pipelines. In fact, over the last 4-5 years, there has been a marked rise in the number of new entrants in this field. We anticipate this upcoming market to witness substantial growth in the coming years.

In addition to other elements, the study includes:

In order to account for the uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

The opinions and insights presented in this study were also influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

Key Questions Answered

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/wgim84

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/blood-brain-barrier-markets-insights-and-forecast-to-2030-by-type-of-molecule-target-disease-indications-key-contributing-technologies-leading-drug-developers-and-key-geographical-regions-301061789.html

SOURCE Research and Markets

Link:
Blood-Brain Barrier Markets Insights and Forecast to 2030 by Type of Molecule, Target Disease Indications, Key Contributing Technologies, Leading Drug...

Recommendation and review posted by Bethany Smith

Facts & Factors Market Research added a recent report on Cancer Gene Therapy Market By Type (Ex-vivo and In-vivo) and By Product (Viral Vectors, Non-viral Vectors, and Others): Global Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecasts, 20202026 to its research database. The Cancer Gene Therapy Market research report is an output of a brief assessment and an extensive analysis of practical data collected from the global industry.

This specialized and expertise oriented industry research report scrutinizes the technical and commercial business outlook of the Cancer Gene Therapy industry. The report analyzes and declares the historical and current trends analysis of the Cancer Gene Therapy industry and subsequently recommends the projected trends anticipated to be observed in the Cancer Gene Therapy market during the upcoming years.

The Cancer Gene Therapy market report analyzes and notifies the industry statistics at the global as well as regional and country levels to acquire a thorough perspective of the entire Cancer Gene Therapymarket. The historical and past insights are provided for FY 2016 to FY 2019 whereas projected trends are delivered for FY 2020 to FY 2026. The quantitative and numerical data is represented in terms of value from FY 2016 2026.

The quantitative data is further underlined and reinforced by comprehensive qualitative data which comprises various across-the-board market dynamics. The rationales which directly or indirectly impact the Cancer Gene Therapy industry are exemplified through parameters such as growth drivers, restraints, challenges, and opportunities among other impacting factors.

Request an Exclusive Free Sample Report of Cancer Gene Therapy Market: https://www.fnfresearch.com/sample/cancer-gene-therapy-market-by-type-ex-vivo-898

Our Every Free Sample Includes:

A research report overview, TOC, list of tables and figures, an overview of major market players and key regions included.

Some of Top Market Players Analysis Included in this Report:

Vigene Biosciences, Sirion Biotech, Bluebird bio, Cellectis, Ziopharm, Cobra, Uniqure, Finvector, Sarepta Therapeutics

The Market Player Analysis based on some of below Factors:

Inquire more about this report before purchase @ https://www.fnfresearch.com/inquiry/cancer-gene-therapy-market-by-type-ex-vivo-898

This research report provides forecasts in terms of CAGR, and Y-O-Y growth. This helps to understand the overall market and to recognize the growth opportunities in the global Cancer Gene Therapy Market. The report also includes a detailed profile and information of all the major market players currently active in the global Cancer Gene Therapy Market. The companies covered in the report can be evaluated based on their latest developments, financial and business overview, product portfolio, key trends in the market, long-term and short-term business strategies by the companies to stay competitive in the market.

The global Cancer Gene Therapy Market size & trends are classified based on the types of products, application segments, and end-user. Each segment expansion is assessed together with the estimation of their growth in the upcoming period. The related data and statistics collected from the regulatory organizations are portrayed in the Cancer Gene Therapy Market report to assess the growth of each segment.

The global Cancer Gene Therapy Market size & trends are classified based on the types of products, application segments, and end-user. Each segment expansion is assessed together with the estimation of their growth in the upcoming period. The related data and statistics collected from the regulatory organizations are portrayed in the Cancer Gene Therapy Market report to assess the growth of each segment.

Request Customized Copy of Report @ https://www.fnfresearch.com/customization/cancer-gene-therapy-market-by-type-ex-vivo-898

(We customize your report according to your research need. Ask our sales team for report customization).

Available Customization Options:

The Cancer Gene Therapy Market can be customized to the country level or any other market segment. Besides this, Report understands that you may have your own business need, hence we also provide fully customized solutions to clients.

KEY REPORT POINTERS & HIGHLIGHTS:

To Know More about Discount on Specific Report, Kindly Mail us at [[emailprotected]]with Your requirement. We will send you a quote and discount offer, if available.

About Us:

Facts & Factors is a leading market research company and offers customized research reports and consulting services. Facts & Factors aims at management consulting, industry chain research, and advanced research to assist our clients by providing planned revenue model for their business. Our report and services are used by prestigious academic institutions, start-ups, and companies globally to understand the international and regional business background. Our wide-ranging database offers statistics and detailed analysis of different industries worldwide that help the clients in achieving sustainable progress. The well-organized reports help clients in developing strategies and making informed business decisions.

Contact Us:

Facts & Factors

Global Headquarters

Level 8, International Finance Center, Tower 2,

8 Century Avenue, Shanghai,

Postal 200120, China

Tel: +8621 80360450

E-Mail: [emailprotected]

Web:https://www.fnfresearch.com

Excerpt from:
The Impact of Coronavirus on The Cancer Gene Therapy Market 2020 Projected to Witness Robust Development by 2026 3w Market News Reports - 3rd Watch...

Recommendation and review posted by Bethany Smith

A new study on the Gene Therapy market provides a detailed overview of the demands and consumptions of various products/services associated with the growth dynamics of the market during the historical period 2015 2019. The in-depth market estimation of various opportunities in the segments is expressed in volumes and revenues during the forecast period 2020 2026. The insights and analytics on the Gene Therapy market span several pages. These are covered in numerous sections, including, drivers and restraints, challenges and opportunities, regional segmentation and opportunity assessment, end-use/application prospects analysis, and competitive landscape assessment.Despite the ongoing issues, the worldwide revenue of gene therapy market will surpass US$ 5 Bn by 2026, exhibiting a stellar growth rate.

Key stakeholders in the Gene Therapy market including industry players, policymakers, and investors in various countries have been continuously realigning their strategies and approaches to implement them in order to tap into new opportunities. Many in recent months have overhauled their strategies to remain agile in the backdrop of worldwide disruptions caused by the COVID-19 pandemic.

Request to View Sample of Research Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=4648

The study also offers scrutiny of the changing government policies amid COVID-19 disruptions. Policymakers in developing and developed nations are framing new regulations to meet the continuing macrocosmic shocks by COVID-19 pandemic. The authors of the report have taken into account the impact analysis of the pandemic, and have elaborated on the trends that will be crucial to the upcoming competitive landscape. New entrants, as well as established players who want to emerge as leaders in the post-COVID era, are taking the impact analysis seriously.

The following insights and evaluations are worth knowing for any market participant, helping them in ascertaining the prevailing dynamics and the future trajectories of the Gene Therapy market. They are a part of the estimations of the opportunities in various segments.

Some of the insights and market estimations that make this study unique in approach and effective in guiding stakeholders in understanding the growth dynamics. The study provides:

The regional segmentation of the Gene Therapy market is done as follows:

On the basis of product types, the Gene Therapy market report offers insight into major adoption trends for the following segments:

Key end-users covered in the study include:

Companies profiled in the report are:

To Know More Information about This Report, Ask The Analyst @ https://www.factmr.com/connectus/sample?flag=AE&rep_id=4648

How can Fact.MR Make Difference?

Contact:

Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers, Dubai, United Arab Emirates

MARKET ACCESS DMCC Initiative

Email: sales@factmr.com

Web: https://www.factmr.com/

Press Release- https://www.factmr.com/media-release/1409/global-gene-therapy-market

Read this article:
Gene Therapy Market Revenue Status & Forecast Report 2020 to 2026 - The Cloud Tribune

Recommendation and review posted by Bethany Smith

Review highlights the history, progress and potential of cells of the innate immune system that can be harnessed for treatment of cancer

LA JOLLA, Calif., May 19, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the Company), a clinical-stage immunology company focused on developing treatments that harness the patients innate immune system to fight disease, announced publication of a review article: Killers at the crossroads: The use of innate immune cells in adoptive cellular therapy of cancer in the journal Stem Cells Translational Medicine by May Sabry, PhD and Professor Mark Lowdell, PhD, co-founder and Chief Scientific Officer of INmune Bio, past vice-president (Europe) of the International Society of Cell & Gene Therapy (ISCT) and faculty professor at University College London. The article reviews the potential of harnessing cells of the innate immune system to treat cancer.

I was delighted to be invited to review the exciting array of clinical trials of innate immunotherapies for the specialized translational scientists who read SCTM. The innate immune response is so often overlooked as a therapeutic tool, but its conserved presence throughout evolution suggests that it is the most important mediator of tumor immune surveillance, said Prof Lowdell.

This publication is one of the first to comprehensively review clinical trials of the common innate immune effector cells. It highlights the breadth of innate immunotherapy options and the global interest in harnessing this side of the immune system. Prof. Lowdell has been a leader in identifying how cancer evades innate immune surveillance by NK cells and how to overcome those resistance mechanisms to allow NK cells to attack the tumor.

Of all the innate immune effectors in trial, NK cells have been, and remain, at the forefront. More is understood about the NK:tumour cell interaction than any of the other cells and many of the mechanisms which impair function are understood. Uniquely among the innate immune effector cells, NK cells have been shown to be effective without ex vivo manipulation but with in vivo activation with monoclonal antibodies such as Rituximab and Herceptin and with cytokines such as IL-2 and, more recently, IL-15 derivatives, said Prof Lowdell. In this vein, INmune Bio has developed INKmune, an off-the-shelf therapy to activate a cancer patients NK cells in vivo to attack their own cancer cells. INKmune is scheduled to enter clinical trials in the next 12 months in the treatment of patients with ovarian cancer and high-risk MDS. To learn more about INKmune, please visit our website at http://www.inmunebio.com.

About INmune Bio, Inc.

INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor), cancer (INB03), Alzheimers (XPro595), and NASH (LIVNate). The Natural Killer Cell Priming Platform includes INKmune aimed at priming the patients NK cells to eliminate minimal residual disease in patients with cancer. INmune Bios product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visitwww.inmunebio.com.

Forward Looking Statements

Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03, XPro1595, LIVNate, DN-TNF and INKmune are still in clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. Our two platforms are beginning clinical trials and there cannot be any assurance of the success of these trials. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Companys ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Companys business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Companys filings with the Securities and Exchange Commission, including the Companys Annual Report on Form 10-K, the Companys Quarterly Reports on Form 10-Q and the Companys Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

INmune Bio Contact:David Moss, CFO (858) 964-3720DMoss@INmuneBio.com

Investor Contact:James Carbonara (646) 755-7412James@haydenir.com

Read more from the original source:
Killers at the Crossroad A Published Review of Innate Immune Cell Potential in Treatment of Cancers Published by Co-Founder and CSO of INmune Bio,...

Recommendation and review posted by Bethany Smith

North America, Europe, China, Japan, Rest of the World,May 2020, The Viral Vector & Plasmid DNA Manufacturing Market research report includes an in-sight study of the keyViral Vector & Plasmid DNA Manufacturing Market Researchprominent players along with the company profiles and planning adopted by them. This helps the buyer of the Viral Vector & Plasmid DNA Manufacturing report to gain a clear view of the competitive landscape and accordingly plan Viral Vector & Plasmid DNA Manufacturing market strategies. An isolated section with top key players is provided in the report, which provides a complete analysis of price, gross, revenue(Mn), Viral Vector & Plasmid DNA Manufacturing specifications, and company profiles. The Viral Vector & Plasmid DNA Manufacturing study is segmented by Module Type, Test Type, And Region.

The market size section gives the Viral Vector & Plasmid DNA Manufacturing market revenue, covering both the historic growth of the market and the forecasting of the future. Moreover, the report covers a host of company profiles, who are making a mark in the industry or have the potential to do so. The profiling of the players includes their market size, key product launches, information regarding the strategies they employ, and others. The report identifies the total market sales generated by a particular firm over a period of time. Industry experts calculate share by taking into account the product sales over a period and then dividing it by the overall sales of the Viral Vector & Plasmid DNA Manufacturing industry over a defined period.

Download Full PDF Sample Copy of Report:jcmarketresearch.com/report-details/11639/sample

The research covers the current market size of the Viral Vector & Plasmid DNA Manufacturing Market Researchand its growth rates based on 5 year history data. It also covers various types of segmentation such as by geography North America, Europe, Asia-Pacific etc., by product type Viral Vector & Plasmid DNA Manufacturing Market Research, by applications Biopharmaceutical Companies Research Institutes Main Ain overall market. The in-depth information by segments of Viral Vector & Plasmid DNA Manufacturing market helps monitor performance & make critical decisions for growth and profitability. It provides information on trends and developments, focuses on markets and materials, capacities, technologies, CAPEX cycle and the changing structure of the Viral Vector & Plasmid DNA Manufacturing Market Research.

This study also contains company profiling, product picture and specifications, sales, market share and contact information of various international, regional, and local vendors of Viral Vector & Plasmid DNA Manufacturing Market Research. The market competition is constantly growing higher with the rise in technological innovation and M&A activities in the industry. Moreover, many local and regional vendors are offering specific application products for varied end-users. The new vendor entrants in the market are finding it hard to compete with the international vendors based on quality, reliability, and innovations in technology.

Global Viral Vector & Plasmid DNA Manufacturing (Thousands Units) and Revenue (Million USD) Market Split by Product Type such as Adenovirus Retrovirus Plasmid DNA Others M

The research study is segmented by Application such as Laboratory, Industrial Use, Public Services & Others with historical and projected market share and compounded annual growth rate.Global Viral Vector & Plasmid DNA Manufacturing (Thousands Units) by Regions (2019-2025)

Geographically,this report is segmented into several key Regions, with production, consumption, revenue (million USD), and market share and growth rate of Viral Vector & Plasmid DNA Manufacturing in these regions, from 2012 to 2022 (forecast), covering

Get Exclusive Discount:jcmarketresearch.com/report-details/11639/discount

There are 15 Chapters to display theViral Vector & Plasmid DNA Manufacturing Market Research.

Chapter 1, to describe Definition, Specifications and Classification of Viral Vector & Plasmid DNA Manufacturing , Applications of Viral Vector & Plasmid DNA Manufacturing , Market Segment by Regions;

Chapter 2, to analyze the Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;

Chapter 3, to display the Technical Data and Manufacturing Plants Analysis ofViral Vector & Plasmid DNA Manufacturing, Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;

Chapter 4, to show the Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis by Merck uniQure The Cell and Gene Therapy Catapult Waisman Biomanufacturing Addgene Creative Biogene Novasep Cobra Biologics Aldevron;

Chapter 5 and 6, to show the Regional Market Analysis that includes North America, Europe, Asia-Pacific etc.,Viral Vector & Plasmid DNA ManufacturingSegment Market Analysis Adenovirus Retrovirus Plasmid DNA Others M;

Chapter 7 and 8, to analyze theViral Vector & Plasmid DNA ManufacturingSegment Market Analysis (by Application) Major Manufacturers Analysis ofViral Vector & Plasmid DNA Manufacturing;Merck uniQure The Cell and Gene Therapy Catapult Waisman Biomanufacturing Addgene Creative Biogene Novasep Cobra Biologics Aldevron

Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type Adenovirus Retrovirus Plasmid DNA Others M, Market Trend by Application Biopharmaceutical Companies Research Institutes Main A;

Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;

Chapter 11, to analyze the Consumers Analysis ofViral Vector & Plasmid DNA Manufacturing;

Chapter 12, to describeViral Vector & Plasmid DNA ManufacturingResearch Findings and Conclusion, Appendix, methodology and data source;

Chapter 13, 14 and 15, to describeViral Vector & Plasmid DNA Manufacturingsales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

Enquiry before Buying The full report @:jcmarketresearch.com/report-details/11639/enquiry

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Author:JCMR global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the Accurate Forecast in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their Goals & Objectives.

Contact Us:JCMARKETRESEARCHJay (Marketing Manager)Phone:+1 (925) 478-7203Email:[emailprotected]

More:
Viral Vector & Plasmid DNA Manufacturing Market Rising Growth With Keyplayer: Merck uniQure The Cell and Gene Therapy Catapult Waisman...

Recommendation and review posted by Bethany Smith

Global Viral Clearance Market is expected to rise from its initial estimated value of USD 517million in 2016 to an estimated value of USD 2457 million by 2026, registering a CAGR of 21.50% in the forecast period of 2016-2026. Increasing investment on R&D is driving the growth of this market.Some of the major players operating in global viral clearance market areInternational, Inc., Lonza, Sigma-Aldrich Co., Wuxi Pharmatech (Cayman) Inc., Merck & Co., Thermo Fisher Scientific Inc., Texcell, BSL Bioservice, Avance Biosciences, SGS SA, Eurofins Scientific, General Electric, Danaher, Sartorius AG, Agilent Technologies, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Pfizer Inc., Hospitech, CSL Behring, Illumina, Inc., Eppendorf AG, PromoCell GmbH, HiMedia Laboratories, BD, Biospherix, Ltd, , and Novogene Corporation among others

Get Sample Report + All Related Graphs & Charts @http://databridgemarketresearch.com/request-a-sample/?dbmr=global-viral-clearance-market

Competitive Analysis:

Global viral clearance market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of viral clearance market for Global, Europe, North America, Asia Pacific, South America, Middle East & Africa.

Global Viral Clearance Market By Method (Viral Detection Method, Viral Removal, Viral Inactivation), Application (Vaccines and Therapeutics, Blood and Blood Products, Cellular and Gene Therapy Products, Tissue and Tissue Products, Stem Cell Products), End-User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic Research Institutes), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2026

Market Definition:

Viral clearance is stated as the removal of contaminated viral by chromatography technique. The development process for monoclonal antibodies, blood derived product , glycoprotein and recombinant protein. To ensure that therapeutic drugs derived from certain sources are fully rid of any viral contamination, these protein solutions undergo viral clearance to inactivate or remove viral materials.

Market Drivers

Market Restraints

Grab Your Report at an Impressive Discount! Please click[emailprotected]https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-viral-clearance-market

Segementation: Global Viral Clearance Market

By Method

By Application

By End User

By Geography

Key Developments in the Market:

Reasons to Purchase this Report

Key Insights in the report:

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

See the original post:
Global Viral Clearance Market is Thriving with Rising Latest Trends by 2027 | Top Players- International, Inc., Lonza, Sigma-Aldrich Co., Wuxi...

Recommendation and review posted by Bethany Smith

Detailed Study on the Global Gene Therapy Market

A recent market study throws light on some of the leading factors that are likely to influence the growth of the Gene Therapy market in the upcoming decade. The well-researched market study touches upon the growth potential of various budding market players in the current Gene Therapy market landscape. Moreover, established players, stakeholders, and investors can leverage the data in the report to formulate effective growth strategies.

As per the report, the Gene Therapy market is forecasted to reach a value of ~US$XX by the end of 2029 and grow at a CAGR of ~XX% through the forecast period (2019-2029). The key dynamics of the Gene Therapy market including the drivers, restraints, opportunities, and trends are thoroughly analyzed in the presented report.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2653033&source=atm

The Research Aims to Addresses the Following Doubts Pertaining to the Gene Therapy Market

The report on the Gene Therapy market provides a birds eye view of the current proceeding within the Gene Therapy market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Gene Therapy market and offers a clear assessment of the projected market fluctuations during the forecast period. The different factors that are likely to impact the overall dynamics of the Gene Therapy market over the forecast period (2019-2029) including the current trends, growth opportunities, restraining factors, and more are discussed in detail in the market study.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2653033&source=atm

Gene Therapy Market Segmentation

Competitive Landscape

The competitive landscape section of the report elaborates on the recent developments and innovations introduced by prominent players in the Gene Therapy market. The growth potential, revenue growth, product range, and pricing strategies of each market player in inspected in the report with precision.

End-use Industry Assessment

The report segments the Gene Therapy market on the basis of end-use industry and offers a detailed understanding of the supply-demand ratio and consumption pattern of the Gene Therapy in each end-use industry.

Regional and Country-level AnalysisThe report offers an exhaustive geographical analysis of the global Gene Therapy market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.Competition AnalysisIn the competitive analysis section of the report, leading as well as prominent players of the global Gene Therapy market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Gene Therapy market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Gene Therapy market.The following players are covered in this report:Bluebird BioSangamoSpark TherapeuticsDimension TherapeuticsAvalanche BioCelladonVical Inc.AdvantageneGene Therapy Breakdown Data by TypeEx vivoIn VivoGene Therapy Breakdown Data by ApplicationCancerMonogenicInfectious diseaseCardiovascular diseaseOther

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2653033&licType=S&source=atm

Essential Findings of the Gene Therapy Market Report:

See the original post here:
Coronavirus' business impact: Gene Therapy Market 2019 By Advancements, Application, Challenges, Trends, Top Key Players, Growth & Forecast Till...

Recommendation and review posted by Bethany Smith

Global Antiaging Products and Services Market analysis report is a historical overview and all-inclusive study on the current & future market of the Healthcare industry. This market study has been analyzed and takes into account the CAGR of the market, valuation, volume, revenue including historical and forecast, sales (current and future), and other significant factors related to the global market. Antiaging Products and Services Market business document puts forward an in-depth assessment of each crucial aspect of the worldwide market that relates to the market size, market share, market growth factor, key vendors, revenue, top regions, industry trends, product demand, sales volume, capacity, cost structure & expansion in the market.

Request for Sample Copy or PDF Herehttps://www.databridgemarketresearch.com/request-a-sample?dbmr=global-antiaging-products-and-services-market

Theglobal antiaging products and services marketis expected to reach USD 859.11 billion by 2025, from USD 347.58 billion in 2017 growing at a CAGR of 11.8% during the forecast period of 2018 to 2025. The upcoming market report contains data for historic year2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

Some of the major players operating in the globalantiaging products and services marketareChanel SA, GlaxoSmithKline Plc, Allergan Inc, Neutrogena Corporation, Procter & Gamble, Elizabeth Arden Inc, Johnson & Johnson, Orlane SA, Revlon Inc, Novartis International AG, Unilever PLC, Avon Products Inc, Woodridge Labs Inc, Beiersdorf, LOral SA, Merck & Company Inc, Christian Dior, Valeant Pharmaceuticals International, NeoStrata Company Inc, Bayer Schering Pharma AG, F. Hoffmann-La Roche Ltd among others.

Market Definition:Global Antiaging Products and Services Market

As the skin ages, it loses its natural elasticity and becomes thinner, more fragile and laxer, taking on a wrinkled appearance. In modern society, there is a great increase in the search for eternal youth and an insatiable appetite for methods which could turn back the clock. This has triggered an explosion in the antiaging industry. In addition, technological advances in medicine for the prevention and treatment of deadly diseases help to increase life expectancy.

The aging process of the skin generally has two kinds of forms: natural aging and light aging. There are various factors which directly affect intrinsic aging such as ethnicity, anatomic variations, hormonal changes, extrinsic aging, drugs, smoking and sunlight exposure. These aging conditions can be treated by the antiaging products such as UV absorbers, anti-wrinkle products, anti-stretch products, others and services and therapies. For anti-aging, the cosmetics are commercially available products that can be used to improve the appearance of the skin. People are constantly demanding for more effective products that can essentially beautify the appearance and has resulted in augmented basic science research and product development in the cosmetics industry.

According to news provided by Stempeutics Research Pvt. Ltd., in July 2015, Cipla (India) launched a new anti-aging product which uses human bio-active factors. The product was launched with a brand name Cutisera, developed by Stempeutics. This product will be used for reducing fine lines and wrinkles, lightening dark spots, evening skin tone, improving skin firmness and improving skin hydration.

Browse Detailed TOC Herehttps://www.databridgemarketresearch.com/toc?dbmr=global-antiaging-products-and-services-market&raksh

Market Segmentation:Global Antiaging Products and Services Market

The global antiaging products and services market is segmented based on product, therapies and services and geographical segments.

Based on product, the market is segmented into UV absorbers, anti-wrinkle products, anti-stretch products and others.

Based on therapies and services, the market is segmented into eye-lid surgery, abdominoplasty, hormone replacement therapy, breast augmentation, liposuction, gene therapy, injectable skin, botox, telomere based therapy, rejuvenation and dermal fillers, sclerotherapy, anti-pigmentation therapy, hair restoration services and chemical peels.

Based on geography, the market report covers data points for 28 countries across multiple geographies namely North America & South America, Europe, Asia-Pacific and, Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa and, Brazil among others.

Major Market Drivers and Restraints:

Key Developments in the Market:

Competitive Analysis:Global Antiaging Products and Services Market

The global antiaging products and services market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of antiaging products and services market for global, Europe, North America, Asia Pacific and South America.

Reasons to Purchase this Report

Customization of the Report

Want Full Report? Enquire Herehttps://www.databridgemarketresearch.com/inquire-before-buying?dbmr=global-antiaging-products-and-services-market&raksh

About Data Bridge Market Research:

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475 Mail:[emailprotected]

See the article here:
Antiaging Products and Services Market Competitive Strategies and Worldwide Demand with Top Players Elizabeth Arden Inc, Johnson & Johnson,...

Recommendation and review posted by Bethany Smith

Vertex Pharmaceuticals (VRTX) is the $75 billion champion of cystic fibrosis (CF) who is expected to grow sales 37% this year to $5.7 billion -- after a 37% topline advance last year.

Since 2012, Vertex has developed a suite of drug treatments for CF, including the "triple threat" combo Trikafta, which was approved by the FDA in October 2019.

Cystic fibrosis is a hereditary disease that affects the lungs and digestive system. The body produces thick and sticky mucus that can clog the lungs and obstruct the pancreas. CF can be life-threatening, and people with the condition tend to have a shorter-than-normal life span, with many adults not making it to their 30th birthday.

Vertexs lead marketed products are Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor in combination with ivacaftor), Orkambi (lumacaftor in combination with ivacaftor) and Kalydeco (ivacaftor), which are collectively approved to treat around 60% of the 75,000 CF patients in North America, Europe and Australia.

Trikafta, approved in people aged 12 years and older who have at least one F508del mutation, is under review in Europe and is also being evaluated in younger patients in the United States. With approval of Trikafta, Vertex can address a significantly larger CF patient population almost 90% of patients with CF in the future.

Q1 Quarter and Outlook

Despite COVID-19 related uncertainty, Vertexs sales in 2020 are being driven by rapid uptake of Trikafta and higher international revenues due to reimbursement arrangements in key ex-U.S. countries. Trikaftas early approval and launch was a significant milestone for Vertex.

On April 29, Vertex reported Q1 results and beat estimates for earnings and sales. The 2020 outlook sparked analysts to raise EPS estimates significantly with this year getting boosted 15.8% from $7.60 to $8.80, representing 65% growth.

The company recorded total revenues of $4.16 billion in 2019, up 37%. Orkambi accounted for 29.4% of the companys total product revenues, Kalydeco accounted for 24.7%, Symdeko accounted for 35.4% and Trikafta comprised 10.5% of the same.

Vertexs dependence on the CF franchise for growth is a concern, especially as competitors would only erode market share. But Vertexs non-CF pipeline is progressing rapidly with data in multiple disease arenas expected in 2020: sickle cell disease, thalassemia and pain management.

Vertex + CRISPR = Potential Knockout Punch for Blood Disorders

Vertex is co-developing a gene editing treatment, CTX001 in partnership with CRISPR Therapeutics (CRSP) in two devastating diseases sickle cell disease and thalassemia. Phase I/II studies of CTX001 in adult transfusion-dependent b-thalassemia in Europe and sickle cell disease in the United States are ongoing.

In June 2019, Vertex announced expansion of its collaboration with CRISPR Therapeutics and acquisition of privately held Exonics Therapeutics to boost its gene editing capabilities to develop novel therapies for Duchenne muscular dystrophy (DMD) and Myotonic dystrophy type 1 (DM1).

In the April 29 update, Vertex and partner CRISPR Therapeutics said they remain on track to provide additional data from the two ongoing Phase 1/2 studies of the investigational CRISPR/Cas9 gene-editing therapy CTX001 in patients with transfusion-dependent beta thalassemia and in patients with severe sickle cell disease in 2020.

Bottom line for VRTX: The COVID-19 crisis has put the Biotech sector in the spotlight and dozens of companies are responding with resourceful R&D and robust adaptations to clinical trial interruptions. Vertex is a strong leader here and should be part of any growth-oriented healthcare-focused portfolio.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.

This outperformance has not just been a recent phenomenon. From 2000 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.

See their latest picks free >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportVertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis ReportCRISPR Therapeutics AG (CRSP) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

View original post here:
Bull of the Day: Vertex Pharma (VRTX) - Yahoo Finance

Recommendation and review posted by Bethany Smith

It's not clear from the contracting notice if the land-based design would actually be the only replacement for the T-45, as NAVAIR itself has made clear that it will only be able to meet "certain requirements" for the UJTS program. The War Zone has already reached out for additional information and clarification.

It's certainly true that the T-45s, of which the Navy and the Marine Corps have around 194 in service in total, the oldest of which are now more than three decades old, are increasingly in need of a replacement. The Navy had originally planned to phase them all out in 2018, but, five years before, made to decision to instead extend their service life through 2042. The Goshawks fleet's readiness rates have slipped in recent years, raising concerns about the service's ability to train an adequate number of pilots each year. In 2019, the Government Accountability Office also warned about potential shortfalls in available aircraft as jets went through the planned Service Life Extension Program.

The T-45 fleet also suffered a worrying and deadly spate of hypoxia incidents between 2016 and 2017. Various fixes to the aircraft themselves, as well as the Navy's operating procedures, have reduced the number of subsequent physiological events in the past three years, but identifying the underlying root causes has proven difficult.

Buying an existing land-based design made to Navy specifications, but without having to modify it to withstand the stresses of catapult launches and arrested landings, could offer a low-cost, low-risk path for the Navy to acquire new jet trainers. One obvious option would be to acquire a version of the U.S. Air Force's new T-7A Red Hawk, the production of which started in January. The War Zone has already detailed the many possible future roles for the T-7A, or derivatives thereof, in the past.

There are also a number of other proven and in-production land-based jet trainer designs available, including the losing entrants for the Air Force's T-X competition, which the T-7A won. The Air Force itself recently exploring buying a small number of South Korean-made KAI T-50 Golden Eagles to support its own transformational fighter jet pilot training plans. That service canceled its proposed sole-source purchase of the T-50s in March and now says it will hold an open competition.

At the same time, whatever cost-savings the Navy might find by pursuing this course of action might be offset, at least in part, by changes that would then be necessary to its fighter pilot training pipeline. Those aviators will still need to conduct carrier qualifications and will need suitable aircraft in which to perform them. Even simply using existing F/A-18E/F Super Hornets to meet these requirements would increase the number of flight hours those jets have to dedicate to training missions, potentially pulling them away from other activities. These full-up fighters are also costly to operate.

It is worth noting that the Navy is making substantial investments in developing and fielding various technologies to help automate carrier landings. It is possible that this could eventually reduce the amount of required carrier qualification training the service feels is required, but it wouldn't eliminate it entirely. At the same time, carrier qualifications have been getting steadily pushed farther and farther down the pipeline.

The Navy has already done something broadly similar with regards to its C-2 Greyhound andE-2 Hawkeye aircraft. Prospective pilots destined to fly those aircraft conduct much of their training in the T-44, a variant of the Beechcraft King Air, which is also not carrier-capable. It's not clear how that training pipeline may also now change as the C-2s get replaced by the CMV-22B Osprey tilt-rotor. Still, as long as manned fighter jets operate from its carriers, there will be a need to have those pilots practice the uniquely complicated process of landing on, as well as taking off from, those flattops.

Regardless, the Navy's plans to buy non-carrier-capable jet trainers to replace its T-45s, even in part, points to major changes coming in how the service prepares prospective fighter pilots for the challenges involved in joining its carrier air wings.

Contact the author: joe@thedrive.com

Read more:
The Navy's Next Jet Trainer Won't Be Able To Land Or Take Off From An Aircraft Carrier - The Drive

Recommendation and review posted by Bethany Smith

The Department of Defense has begun to ratchet up spending to recapitalize the U.S. strategic nuclear triad and its supporting infrastructure, as several programs move from research and development into the procurement phase. The projected Pentagon expenditures are at least $167 billion from 2021-2025. This amount does not include the large nuclear warhead sustainment and modernization costs funded by the Department of Energy, projected to cost $81 billion over the next five years.

Nuclear forces require modernization, but that will entail opportunity costs.In a budget environment that offers little prospect of greater defense spending, especially in the COVID19 era, more money for nuclear forces will mean less funding for conventional capabilities.

That has potentially negative consequences for the security of the United States and its allies. While nuclear forces provide day-to-day deterrence, the Pentagon leadership spends most of its time thinking about how to employ conventional forces to manage security challenges around the world. The renewed focus on great power competition further elevates the importance of conventional forces. It is important to get the balance between nuclear and conventional forces right, particularly as the most likely path to use of nuclear arms would be an escalation of a conventional conflict. Having robust conventional forces to prevail in or deter a conventional conflict in the first place could avert a nuclear crisis or worse.

For the foreseeable future, the United States will continue to rely on nuclear deterrence for its security and that of its allies (whether we should be comfortable with that prospect is another question).Many U.S. nuclear weapons systems are aging, and replacing them will cost money, lots of money.The Pentagons five-year plan for its nuclear weapons programs proposes $29 billion in fiscal year 2021, rising to $38 billion in fiscal year 2025, as programs move from research and development to procurement.The plan envisages a total of $167 billion over five years.And that total may be understated; weapons costs increase not just as they move to the procurement phase, but as cost overruns and other issues drive the costs up compared to earlier projections.

The Pentagon knew that the procurement bow wave of nuclear weapons spending would hit in the 2020s and that funding it would pose a challenge.In October 2015, the principal deputy undersecretary of defense said Were looking at that big bow wave and wondering how the heck were going to pay for it and probably thanking our stars that we wont be here to have to answer the question.

The Pentagons funding request for fiscal year 2021 includes $4.4 billion for the new Columbia-class ballistic missile submarine that will replace Ohio-class submarines, which will begin to be retired at the end of the decade; $1.2 billion for the life extension program for the Trident II submarine-launched ballistic missile (SLBM); $1.5 billion for the Ground Based Strategic Deterrent, an intercontinental ballistic missile (ICBM) to replace the Minuteman III ICBM; $2.8 billion for the B-21 stealth bomber that will replace the B-1 and B-2 bombers; $500 million for the Long-Range Standoff Missile that will arm B-52 and B-21 bombers; and $7 billion for nuclear command, control and communications systems.

The Pentagon funds primarily go to delivery and command and control systems for nuclear weapons.The National Nuclear Security Administration at the Department of Energy bears the costs of the warheads themselves. It seeks $15.6 billion for five nuclear warhead life-extension and other infrastructure programs in fiscal year 2021, the first year of a five-year plan totaling $81 billion.The fiscal year 2021 request is nearly $3 billion more than the agency had earlier planned to ask, which suggests these programs are encountering significant cost growth.

Some look at these figures and the overall defense budget (the Pentagon wants a total of $740 billion for fiscal year 2021) and calculate that the cost of building and operating U.S. nuclear forces will amount to only 6-7 percent of the defense budget.That may be true, but how relevant is that figure?

By one estimate, the cost of building and operating the F-35 fighter program for the U.S. Air Force, U.S. Navy and U.S. Marines over the programs lifetime will be $1 trillion.Amortized over 50 years, that amounts to $20 billion per year or only 2.7 percent of the Defense Departments fiscal year 2021 budget request.The problem is that these percentages and lots of other small percentages add up.When one includes all of the programs, plus personnel and readiness costs as well as everything else that the Pentagon wants, the percentages will total to more than 100 percent of the figure that Congress is prepared to appropriate for defense.

The defense budget is unlikely to grow.Opportunity costs represent the things the Pentagon has to give up or forgo in order to fund its nuclear weapons programs.The military services gave an indication of these costs with their unfunded priorities lists, which this year total $18 billion.These show what the services would like to buy if they had additional funds, and that includes a lot of conventional weapons.

The Air Force, for example, would like to procure an additional twelve F-35 fighters as well as fund advance procurement for an additional twelve F-35s in fiscal year 2022. It would also like to buy three more tanker aircraft than budgeted.

The Army is reorienting from counter-insurgency operations in places such as Afghanistan and Iraq to facing off against major peer competitors, that is, Russia and China.Its wish list includes more long-range precision fires (artillery and short-range surface-to-surface missiles), a new combat vehicle, helicopters and more air and missile defense systems.

The Navy would like to add five F-35s to its aircraft buy, but its bigger desire is more attack submarines and warships, given its target of building up to a fleet of 355 ships. The Navy termed a second Virginia-class attack submarine its top unfunded priority in fiscal year 2021.It has set a requirement for 66 attack submarines and currently has about 50.However, as older Los Angeles-class submarines retire, that number could fall to 42. Forgoing construction of a Virginia-class submarine does not help to close that gap.

Moreover, the total number of Navy ships, now 293, will decline in the near term, widening the gap to get to 355.The Navys five-year shipbuilding program cut five of twelve planned Arleigh Burke-class destroyers, and cost considerations have led the Navy to decide to retire ten older Burke-class destroyers rather than extend their service life for an additional ten years.This comes when China is rapidly expanding its navy, and Russian attack submarines are returning on a more regular cycle to the Atlantic Ocean.

The Navy has said that funding the first Columbia-class ballistic missile submarine forced a cut-back in the number of other ships in its fiscal 2021 shipbuilding request.The decision not to fund a second Virginia-class attack submarine appears to stem directly from the unexpected $3 billion plus-up in funding for the National Nuclear Security Administrations fiscal year 2021 programs.

These are the opportunity costs of more nuclear weapons:fewer dollars for aircraft, ships, attack submarines and ground combat equipment for conventional deterrence and defense.

The principal driving factor behind the size of U.S. nuclear forces comes from Russian nuclear forces and doctrine.Diverse and effective U.S. nuclear forces that can deter a Russian nuclear attack should suffice to deter a nuclear attack by any third country.In contrast to the Cold War, the U.S. military no longer seems to worry much about a bolt from the bluea sudden Soviet or Russian first strike involving a massive number of nuclear weapons designed to destroy the bulk of U.S. strategic forces before they could launch.That is because, under any conceivable scenario, sufficient U.S. strategic forcesprincipally on ballistic missile submarines at seawould survive to inflict a devastating retaliatory response.

The most likely scenario for nuclear use between the United States and Russia is a regional conflict fought at the conventional level in which one side begins to lose and decides to escalate by employing a small number of low-yield nuclear weapons, seeking to reverse battlefield losses and signal the strength of its resolve.Questions thus have arisen about whether Russia has an escalate-to-deescalate doctrine and whether the 2018 U.S. nuclear posture review lowers the threshold for use of nuclear weapons.

If the United States and its allies have sufficiently robust conventional forces, they can prevail in a regional conflict at the conventional level and push any decision about first use of nuclear weapons onto the other side (Russia, or perhaps China or North Korea depending on the scenario).The other side would have to weigh carefully the likelihood that its first use of nuclear weapons would trigger a nuclear response, opening the decidedly grim prospect of further nuclear escalation and of things spinning out of control.The other sides leader might calculate that he/she could control the escalation, but that gamble would come with no guarantee. It would appear a poor bet given the enormous consequences if things go wrong.Happily, the test has never been run.

This is why the opportunity costs of nuclear weapons programs matter. If those programs strip too much funding from conventional forces, they weaken the ability of the United States and its allies to prevail in a conventional conflictor to deter that conflict in the first placeand increase the possibility that the United States might have to employ nuclear weapons to avert defeat.

For the United States and NATO members, that could mean reemphasis on an aspect of NATOs Cold War defense policy. In the 1960s, 1970s and early 1980s, NATO allies faced Soviet and Warsaw Pact conventional forces that had large numerical advantages, and NATO leaders had doubts about their ability to defeat a Soviet/Warsaw Pact attack at the conventional level.NATO policy thus explicitly envisaged that, if direct defense with conventional means failed, the Alliance could deliberately escalate to nuclear weapons.That left many senior NATO political and military officials uneasy.Among other things, it raised uncomfortable questions about the willingness of an American president to risk Chicago for Bonn.

Russia found itself in a similar situation at the end of the 1990s.With a collapsing economy following the break-up of the Soviet Union, the Russian government had to cut defense spending dramatically.As its conventional capabilities atrophied, Moscow adopted a doctrine envisaging first use of nuclear weapons to compensate.(In the past fifteen years, as Russias defense spending has increased, a significant amount has gone to modernizing conventional forces.)

The United States and NATO still retain the option of first use of nuclear weapons.If the U.S. president and NATO leaders were to consider resorting to that option, they then would be the ones to have to consider the dicey bet that the other side would not respond with nuclear arms or that, if it did, nuclear escalation somehow could be controlled.

Assuring NATO allies that the United States was prepared to risk Chicago for Bonn consumed a huge amount of time and fair amount of resources during the Cold War.At one point, the U.S. military deployed more than 7000 nuclear weapons in Europe to back up that assurance.Had NATO had sufficiently strong conventional forces, the Alliance would have been able to push that risky decision regarding nuclear first use onto Moscowor even have been able to take comfort that the allies conventional power would suffice to deter a Soviet/Warsaw Pact attack.

In modernizing, maintaining and operating a safe, secure and effective nuclear deterrent, the United States should avoid underfunding conventional forces in ways that increase the prospect of conventional defeat and/or that might tempt an adversary to launch a conventional attack.If Washington gets the balance wildly out of sync, it increases the possibility that the president might face the decision of whether to use nuclear weapons firstknowing that first use would open a Pandoras box of incalculable and potentially catastrophic consequences.

This means that the Department of Defense and Congress should take a hard look at the balance.The Pentagon presumably has weighed the trade-offs, though it is not a unitary actor. Nuclear weapons are our top priority has been the view of the leadership.The trade-offs have been easier to manage in the past several years, when nuclear programs were in the research and development phase, and defense budgets in the first three years of the Trump administration grew.As nuclear programs move into the more expensive procurement phase and the fiscal year 2021 budget shows little increase, the challenge of getting the balance right between nuclear and conventional spending has become more acute.It is not apparent that the Pentagon has weighed the opportunity costs over the next ten-fifteen years under less optimistic budget scenarios.

As for Congress, which ultimately sets and approves the budget, no evidence suggests that the legislative branch has closely considered the nuclear vs. conventional trade-offs.

All that was before COVID19.The response to the virus and dealing with the economic disruption it has caused have generated a multi-trillion-dollar budget deficit in 2020 and likely will push up deficits in at least 2021.It would be wise now to consider the impact of COVID19.

Having added trillions of dollars to the federal deficit, and facing an array of pressing health and social needs, will Congress be prepared to continue to devote some 50 percent of discretionary funding to the Department of Defenses requirements?Quite possibly not.If defense budgets get cut, the Pentagon will face a choice: shift funds from nuclear to conventional force programs, or accept shrinkage of U.S. conventional force capabilities andas the United States did in the 1950s and early 1960srely on nuclear deterrence to address a broader range of contingencies. In the latter case, that would mean accepting, at least implicitly, a greater prospect that the president would have to face the question of first use of nuclear weapons, i.e., a conventional conflict in which the United States was losing.

This is not to suggest that the U.S. military should forgo the strategic triad.Trident II SLBMs onboard ballistic missile submarines at sea remain the most survivable leg of the strategic deterrent.The bomber/air-breathing leg offers flexibility and can carry out conventional missions.The ICBM leg provides a hedge against a breakthrough in anti-submarine warfare.Moreover, if in a crisis or a conventional conflict, the Russian military were to develop the capability to attack U.S. ballistic missile submarines at sea, the Kremlin leadership might well calculate that it could do so without risking a nuclear response.Attacking U.S. ICBMs, on the other hand, would necessitate pouring hundreds of nuclear warheads into the center of America.A Russian leader presumably would not be so foolish as to think there would be no nuclear retaliation.

While sustaining the ICBM leg, one can question whether maintaining 400 deployed ICBMs, as the current plan envisages, is necessary.Reducing that number for the Ground-Based Strategic Deterrent (GBSD) would achieve budget savings, albeit later in the production run. Another question is whether some way might be found to extend the service life of some portion of the current Minuteman III force that would allow delaying the GBSD program, which is projected to cost $100 billion, by ten-fifteen years and postponing those costsfreeing up funds in the near term for conventional force requirements.

Another issue concerns the Long-Range Standoff Missile (LRSO) and its cost, estimated at some $20 billion when including the nuclear warheads.The B-21 bomber will incorporate stealth and advanced electronic warfare capabilities allowing it to operate against and penetrate sophisticated air defenses.The LRSO, to be deployed beginning in 2030, is intended to replace older air-launched cruise missiles carried by the B-52 bomber and could later equip the B-21 if it loses its ability to penetrate.

An alternative plan would convert B-52s in 2030 to conventional-only missions and delay the LRSO to a future point if/when it appeared that the B-21s ability to penetrate could come into question.By 2030, the Air Force should have a significant number of B-21s (the B-21 is scheduled to make its first flight in 2021 and enter service in 2025).With at least 100 planned, the Air Force should have a sufficient number of B-21s for the 300 nuclear weapons it appears to maintain at airfields where nuclear-capable bombers are currently based.

These kinds of ideas would free up billions of dollars in the 2020s that could be reallocated to conventional weapons systems.Delaying the GBSD and LRSO and their associated warhead programs by just one year (fiscal year 2021) would make available some $3 billionenough money for a Virginia-class attack submarine. Delaying those programs for ten-fifteen years would make tens of billions of dollars available for the militarys conventional force needs.

All things being equal, it is smarter and more efficient to choose to make decisions to curtail or delay major programs rather than to continue them until the money runs out and forces program termination. As it examines the administrations proposed fiscal year 2021 defense budget, Congress should carefully consider the trade-offs and press the Pentagon to articulate how it weighed the trade-offs between nuclear and conventional forces. In the end, Congress should understand whether it is funding the force that is most likely to deter not just a nuclear attack, but to deter a conventional conflict that could entail the most likely path to nuclear war.

See original here:
How COVID-19 might affect US nuclear weapons and planning - Brookings Institution

Recommendation and review posted by Bethany Smith